<?xml version="1.0" encoding="UTF-8"?>
<ref id="B23">
 <label>23</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Locke</surname>
    <given-names>FL</given-names>
   </name>
   <name>
    <surname>Neelapu</surname>
    <given-names>SS</given-names>
   </name>
   <name>
    <surname>Bartlett</surname>
    <given-names>NL</given-names>
   </name>
   <name>
    <surname>Siddiqi</surname>
    <given-names>T</given-names>
   </name>
   <name>
    <surname>Chavez</surname>
    <given-names>JC</given-names>
   </name>
   <name>
    <surname>Hosing</surname>
    <given-names>CM</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma</article-title>. 
  <source>Mol Ther</source> (
  <year>2017</year>) 
  <volume>25</volume>(
  <issue>1</issue>):
  <page-range>285–95</page-range>.  
  <pub-id pub-id-type="doi">10.1016/j.ymthe.2016.10.020</pub-id>
 </mixed-citation>
</ref>
